Angiogenesis inhibitors in the treatment of cancer.


The field of cancer research has seen a marked shift in the past decade towards the exploration and development of non-conventional antitumour agents. One of the most widely studied approaches to therapy during this period has been that of antiangiogenesis. The published clinical trials and subsequent FDA approval (in February 2004) of the anti-vascular… (More)


Cite this paper

@article{Rhee2005AngiogenesisII, title={Angiogenesis inhibitors in the treatment of cancer.}, author={Jay W Rhee and Paulo Marcelo Gehm Hoff}, journal={Expert opinion on pharmacotherapy}, year={2005}, volume={6 10}, pages={1701-11} }